deltatrials
Terminated PHASE1 INTERVENTIONAL 2-arm NCT02780128

Next Generation Personalized Neuroblastoma Therapy (NEPENTHE)

Next Generation Personalized Neuroblastoma Therapy (The NEPENTHE Trial)

Sponsor: Foundation Medicine

Conditions Cancer Neuroblastoma
Interventions Biopsy Bone marrow Tests Ceritinib ECG Echocardiogram Eye Exam Interviews Labs Next Generation Sequencing Physical Exam Pregnancy Test Ribociclib Tumor Scans
Updated 19 times since 2017 Last updated: Mar 7, 2026 Started: Jul 31, 2016 Primary completion: Aug 31, 2022 Completion: Aug 31, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The goals of Part 1 (molecular screening) were met, but lack of therapies to match molecular aberrations made Part 2 (treatment) no longer feasible.

Other terminated trials from Foundation Medicine

See all terminations from Foundation Medicine

Other Cancer trials with similar outcome

Browse all Cancer trials

A PHASE1 clinical study on Cancer and Neuroblastoma, this trial is terminated or withdrawn. The trial is conducted by Foundation Medicine and has accumulated 19 data snapshots since 2016. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Mar 2018 · 13 months · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Feb 2019 · 6 months · monthly snapshot~Feb 2019 – ~Aug 2019 · 6 months · monthly snapshot~Aug 2019 – ~Feb 2020 · 6 months · monthly snapshot~Feb 2020 – ~Sep 2020 · 7 months · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Sep 2021 · 7 months · monthly snapshot~Sep 2021 – ~Sep 2022 · 12 months · monthly snapshot~Sep 2022 – ~Mar 2023 · 6 months · monthly snapshot~Mar 2023 – ~Dec 2023 · 9 months · monthly snapshot~Dec 2023 – ~Jul 2024 · 7 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Mar 2025 · 6 months · monthly snapshot~Mar 2025 – ~Mar 2026 · 12 months · monthly snapshot~Mar 2026 – present · 6 months · monthly snapshot

Change History

19 versions recorded

  1. Mar 2026 — Present [monthly]

    Terminated PHASE1

  2. Mar 2025 — Mar 2026 [monthly]

    Terminated PHASE1

  3. Sep 2024 — Mar 2025 [monthly]

    Terminated PHASE1

  4. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1

  5. Dec 2023 — Jul 2024 [monthly]

    Terminated PHASE1

▶ Show 14 earlier versions

  1. Mar 2023 — Dec 2023 [monthly]

    Terminated PHASE1

    Status: Recruiting → Terminated

  2. Sep 2022 — Mar 2023 [monthly]

    Recruiting PHASE1

  3. Sep 2021 — Sep 2022 [monthly]

    Recruiting PHASE1

  4. Feb 2021 — Sep 2021 [monthly]

    Recruiting PHASE1

  5. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE1

  6. Sep 2020 — Jan 2021 [monthly]

    Recruiting PHASE1

  7. Feb 2020 — Sep 2020 [monthly]

    Recruiting PHASE1

  8. Aug 2019 — Feb 2020 [monthly]

    Recruiting PHASE1

  9. Feb 2019 — Aug 2019 [monthly]

    Recruiting PHASE1

  10. Aug 2018 — Feb 2019 [monthly]

    Recruiting PHASE1

  11. Jun 2018 — Aug 2018 [monthly]

    Recruiting PHASE1

  12. Mar 2018 — Jun 2018 [monthly]

    Recruiting PHASE1

  13. Feb 2017 — Mar 2018 [monthly]

    Recruiting PHASE1

  14. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1

    First recorded

Jul 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Foundation Medicine
  • Novartis Pharmaceuticals
  • Yael P Mosse
Data source: Children's Hospital of Philadelphia

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations